NTI164 not checked

Fenix Innovation Group · FEN164

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
2 active
7 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“A CBDA-dominant full-spectrum medicinal cannabis plant extract with extremely low THC.”In the company’s words, NCT07257939 on ClinicalTrials.gov
Tested for
Autism, Autism Spectrum Disorder, Autism Disorder, RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Main trialPhase 3
“This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo. Participants will be randomly allocated to either NTI164 or placebo at a 1:1 ratio and blood samples will be collected and surveys completed at baseline and Week 16. This study will expand efficacy and safety data of NTI164 and provide additional mechanism of action data of NTI164 in this patient cohort.”In the company’s words, NCT07257939 on ClinicalTrials.gov
Other names
FEN164

Other drugs for Autism

All 7 drugs for Autism

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 1 Jul 2029 NTI164 in Autism Spectrum Disorder
Phase 2/3Not yet recruiting 1 Oct 2028 Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
Phase 2/3Completed 1 Mar 2024 Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder
Phase 1/2Completed 1 Sep 2022 Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.
Phase 1/2Completed 1 Dec 2025 Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Phase 1/2Completed 1 Dec 2025 Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)
Phase 1Completed 1 Jun 2025 NTI164 Human PK Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow NTI164

Following is part of Solo: you see every change to NTI164 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in